タイトルをクリックすると、論文の概要を読むことが出来ます。
論文ALL list
- FBXO22 deficiency defines a pleiotropic syndrome of growth restriction and multi-system anomalies associated with a unique epigenetic signature. Navin B Ramakrishna, Umar Bin Mohamad Sahari, Yoshikazu Johmura, Nur Ain Ali, Malak Alghamdi, Peter Bauer, Suliman Khan, Natalia Ordoñez, Mariana Ferreira, Jorge Pinto Basto, Fowzan S Alkuraya, Eissa Ali Faqeih, Mari Mori, Naif A M Almontashiri, Aisha Al Shamsi, Gehad ElGhazali, Hala Abu Subieh, Mode Al Ojaimi, Ayman W El-Hattab, Said Ahmed Said Al-Kindi, Nadia Alhashmi, Fahad Alhabshan, Abdulaziz Al Saman, Hala Tfayli, Mariam Arabi, Simone Khalifeh, Alan Taylor, Majid Alfadhel, Ruchi Jain, Shruti Sinha, Shruti Shenbagam, Revathy Ramachandran, Umut Altunoğlu, Anju Jacob, Nandu Thalange, Mireille El Bejjani, Arnaud Perrin, Jay W Shin, Almundher Al-Maawali, Azza Al-Shidhani, Amna Al-Futaisi, Fatma Rabea, Ikram Chekroun, Mohamed A Almarri, Tomohiko Ohta, Makoto Nakanishi, Alawi Alsheikh-Ali, Fahad R Ali, Aida M Bertoli-Avella, Bruno Reversade, Ahmad Abou Tayoun. Am J Hum Genet. 112, 1–14 May 1, 2025.
- Prognostic Impact of Stimulator of Interferon Genes Expression in Triple Negative Breast Cancer. Tetsuyo Maeda, Makiko Ono, Tomo Osako, Tomohiro Chiba, Satoko Baba, Asumi Iesato, Yukinori Ozaki, Yuka Inoue, Natsue Uehiro, Yoko Takahashi, Takayuki Kobayashi, Takahiro Kogawa, Tomohiko Ohta. Cancer Med. 14(4):e70666, 2025.
- Inflammation and tumor immune escape in response to DNA damage. Nihira Taira Naoe, Rei Kudo, Ohta Tomohiko. Seminars in Cancer Biology. 110, 36-45, 2025.
- Nuclear PD-L1 triggers tumour-associated inflammation upon DNA damage. Naoe T Nihira, Wenwen Wu, Mitsue Hosoi, Yukiko Togashi, Shigeaki Sunada, Yasuo Miyoshi, Yoshio Miki, Tomohiko Ohta. EMBO Rep.2025.
- Ribosomal S6 kinase (RSK) plays a critical role in DNA damage response via the phosphorylation of histone lysine demethylase KDM4B. Wenwen Wu, Jing Zhu, Naoe Taira Nihira, Yukiko Togashi, Atsushi Goda, Junki Koike, Kiyoshi Yamaguchi, Yoichi Furukawa, Takuya Tomita, Yasushi Saeki, Yoshikazu Johmura, Makoto Nakanishi, Yasuo Miyoshi & Tomohiko Ohta. Breast Cancer Research. 26, Article number: 146, 2024.
- The Potential Impact of BI-D1870, a Ribosomal S6 Kinase Inhibitor, on PD-L1 Expression Control. Nihira Taira Naoe, Takeyama Tomohiro, Wu Wenwen and Ohta Tomohiko. The St. Marianna Medical Journal. 15, 45-52, 2024.
- Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma. Nakagawa S, Miyashita M, Maeda I, Goda A, Tada H, Amari M, Kojima Y, Tsugawa K, Ohi Y, Sagara Y, Sato M, Ebata A, Shoji NH, Suzuki T, Nakanishi M, Ohta T, Ishida T. Breast Cancer Res Treat. 2024.
- Editorial: Community Series in Post-Translational Modifications of Proteins in Cancer Immunity and Immunotherapy, Volume II. Nihira NT, Ohta T, Liu Z, Dai X. Front. Immunol. 14:1289016, 2023.
- Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers. Mori T, Okamoto Y, Mu A, Ide Y, Yoshimura A, Senda N, Kawata YI, Kawashima M, Kitao H, Tokunaga E, Miyoshi Y, Ohsumi S, Tsugawa K, Ohta T, Katagiri T, Ohtsuru S, Koike K, Ogawa S, Toi M, Iwata H, Nakamura S, Matsuo K, Takata M. Cancer Med. 12(6):6594-6602, 2023.
- Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance. Zhu J, Wu W, Togashi Y, Nihira NT, Johmura Y, Zhu D, Nakanishi M, Miyoshi Y, Ohta T. Breast Cancer. 29:1076-1087, 2022.
- The ZZ domain of HERC2 is a receptor of arginylated substrates. Tencer AH, Liu J, Zhu J, Burkholder NT, Zhang Y, Wu W, Strahl BD, Ohta T, Kutateladze TG. Sci Rep. 12:6063, 2022.
- Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors. Suzuki Y, Wu W, Ohta T, Hayashi S. Breast Cancer. 29(1):77-91, 2022.
- RNF168 E3 ligase participates in ubiquitin signaling and recruitment of SLX4 during DNA crosslink repair. Katsuki Y, Abe M, Park SY, Wu W, Yabe H, Yabe M, Attikum HV, Nakada S, Ohta T, Seidman MM, Kim Y, Takata M. Cell Rep. 37(4):109879, 2021.
- Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast. Nagasawa S, Kuze Y, Maeda I, Kojima Y, Motoyoshi A, Onishi T, Iwatani T, Yokoe T, Koike J, Chosokabe M, Kubota M, Seino H, Suzuki A, Seki M, Tsuchihara K, Inoue E, Tsugawa K, Ohta T, Suzuki Y. Commun Biol. 4:438, 2021.
- TP53/p53-FBXO22-TFEB controls basal autophagy to govern hormesis. Suzuki N, Johmura Y, Wang TW, Migita T, Wu W, Noguchi R, Yamaguchi K, Furukawa Y, Nakamura S, Miyoshi I, Yoshimori T, Ohta T, Nakanishi M. Autophagy. 17(11):3776-3793, 2021.
- HERC2 inactivation abrogates nucleolar localization of RecQ helicases BLM and WRN. Zhu M, Wu W, Togashi Y, Liang W, Miyoshi Y, Ohta T. Sci Rep. 11:360, 2021.
- FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling and metastasis. Johmura Y, Harris A, Ohta T, Nakanishi M. Cancer Sci. 111(8):2718-2725, 2020.
- HERC2 regulates RPA2 by mediating ATR-induced Ser33 phosphorylation and ubiquitin-dependent degradation. Lai Y, Zhu M, Wu W, Rokutanda N, Togashi Y, Liang W, Ohta T. Sci Rep. 9:14257, 2019.
- Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer. Johmura Y, Maeda I, Suzuki N, Wu W, Goda A, Morita M, Yamaguchi K, Yamamoto M, Nagasawa S, Kojima Y, Tsugawa K, Inoue N, Miyoshi Y, Osako T, Akiyama F, Maruyama R, Inoue J, Furukawa Y, Ohta T, Nakanishi M. J Clin Invest. 128(12):5603-5619, 2018.
- Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells. Imanishi S, Umezu T, Kobayashi C, Ohta T, Ohyashiki K, Ohyashiki JH. Front Pharmacol. 9:1166, 2018.
- HERC2 facilitates BLM and WRN helicase complex interaction with RPA to suppress G-quadruplex DNA. Wu W, Rokutanda N, Takeuchi J, Lai Y, Maruyama R, Togashi Y, Nishikawa H, Arai N, Miyoshi Y, Suzuki N, Saeki Y, Tanaka K, Ohta T. Cancer Res. 78(22):6371-6385, 2018.
- HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks. Wu W, Togashi Y, Johmura Y, Miyoshi Y, Nobuoka S, Nakanishi M, Ohta T. Cancer Sci. 107(10):1406-1415, 2016.
- Functional link between BRCA1 and BAP1 through histone H2A, heterochromatin and DNA damage response. Fukuda T, Tsuruga T, Kuroda T, Nishikawa H, Ohta T. Curr Cancer Drug Targets. 16(2):101-109, 2015.
- Liganded ERα stimulates the E3 ubiquitin ligase activity of UBE3C to facilitate cell proliferation. Okada M, Ohtake F, Nishikawa H, Wu W, Saeki Y, Takana K, Ohta T. Mol Endocrinol. 29(11):1646-1657, 2015.
- The BARD1/HP1 interaction: another clue about heterochromatin involvement in homologous recombination. Fukuda T, Tsuruga T, Kuroda T, Takeuchi J, Wu W, Ohta T. Molecular & Cellular Oncology. 2(2):e1-e7, 2015.
- Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage. Wu W, Nishikawa H, Fukuda T, Vittal V, Asano M, Miyoshi Y, Klevit RE, Ohta T. Cancer Res. 75(7):1311-1321, 2015.
- Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage. Fukuda T, Wu W, Okada M, Maeda I, Kojima Y, Hayami R, Miyoshi Y, Tsugawa K, Ohta T. Cancer Sci. ;106(8):1050-1056, 2015.
- MED12 exon 2 mutations in phyllodes tumors of the breast. Nagasawa S, Maeda I, Fukuda T, Wu W, Hayami R, Kojima Y, Tsugawa KI, Ohta T. Cancer Med. 4(7):1117-21, 2015.
- Ubiquitin acetylation inhibits polyubiquitin chain elongation. Ohtake F, Saeki Y, Sakamoto K, Ohtake K, Nishikawa H, Tsuchiya H, Ohta T, Tanaka K, Kanno J. EMBO Rep. 16(2):192-201, 2015.
- Dysregulation of Retinoic Acid Receptor Diminishes Hepatocyte Permissiveness to Hepatitis B Virus Infection through Modulation of Sodium Taurocholate Cotransporting Polypeptide (NTCP) Expression. Tsukuda S, Watashi K, Iwamoto M, Suzuki R, Aizaki H, Okada M, Sugiyama M, Kojima S, Tanaka Y, Mizokami M, Li J, Tong S, Wakita T. J Biol Chem. 290(9):5673-5684, 2015.
- NF-kB signaling mediates acquired resistance after PARP inhibition. Nakagawa Y, Sedukhina AS, Okamoto N, Nagasawa S, Suzuki N, Ohta T, Hattori H, Roche-Molina M, Narváez AJ, Jeyasekharan AD, Bernal JA, Sato K. Oncotarget. 6(6):3825-3839, 2015.
- LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition. Nagasawa S, Sedukhina AS, Nakagawa Y, Maeda I, Kubota M, Ohnuma S, Tsugawa K, Ohta T, Roche-Molina M, Bernal JA, Narváez AJ, Jeyasekharan AD, Sato K. PLoS One. 10(2):e0118002, 2015.
- Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy. Watanabe Y, Maeda I, Oikawa R, Wu W, Tsuchiya K, Miyoshi Y, Itoh F, Tsugawa K.I, Ohta T. Genes to Cells. 18(12):1120-1130, 2013.
- A DNA-Damage Selective Role for BRCA1 E3 Ligase in Claspin Ubiquitylation, CHK1 Activation, and DNA Repair. Sato K, Sundaramoorthy E, Rajendra E, Hattori H, Jeyasekharan AD, Ayoub N, Schiess R, Aebersold R, Nishikawa H, Sedukhina AS, Wada H, Ohta T, Venkitaraman AR. Curr Biol. 22:1659-66, 2012.
化学療法感受性を左右するBRCA1のE3活性のメカニズムのひとつが明らかになりました。 - HERC2 Interacts with Claspin and regulates DNA origin firing and replication fork progression. Izawa N, Wu W, Sato K, Nishikawa H, Kato A, Boku N, Itoh F, Ohta T. Cancer Res. 71(17):5621-5, 2011.
BRCA1のE3リガーゼであるHERC2がDNA複製を調節していることがわかりました。
- The BRCA1 ubiquitin ligase and homologous recombination repair. Ohta T, Sato K, Wu W. FEBS Lett. 585(18):2836-44, 2011.
- Hoxb4 transduction down-regulates Geminin protein, providing hematopoietic stem and progenitor cells with proliferation potential. Ohno Y, Yasunaga S, Ohtsubo M, Mori S, Tsumura M, Okada S, Ohta T, Ohtani K, Kobayashi M, Takihara Y. Proc Natl Acad Sci U S A. 107(50):21529-34, 2010.
- Recruitment of phosphorylated NPM1 to sites of DNA damage through RNF8-dependent ubiquitin conjugates. Koike A, Nishikawa H, Wu W, Okada Y, Venkitaraman AR, Ohta T. Cancer Res. 70(17):6746-56, 2010.
BRCA1にユビキチン化される基質であるNPM1がリン酸化依存的にDNA二本鎖切断部位のユビキチン鎖にリクルートされる相同組換え修復因子の一つであることを発見しました。
- HERC2 is an E3 ligase that targets BRCA1 for degradation. Wu W, Sato K, Koike A, Nishikawa H, Koizumi H, Venkitaraman AR, Ohta T. Cancer Res. 70(15):6384-92, 2010.
BARD1から解離したBRCA1をユビキチン化し、分解に導くユビキチンリガーゼとしてHERC2を同定しました。
- A mitotic role for the DNA damage-reponsive CHK2 kinase. Sato K, Ohta T, Venkitaraman AR. Nat Cell Biol. 12(5):424-5, 2010.
- Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Asakawa H, Koizumi H, Koike A, Takahashi M, Wu W, Iwase H, Fukuda M, Ohta T. Breast Cancer Res. 12(2):R17, 2010.
- Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction (Review). Ohta T, Wu W, Koike A, Asakawa H, Koizumi H, and Fukuda M. Breast Cancer. 16(4):268-74, 2009.
- Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T. Breast Cancer. 17(2):118-24, 2010.
- Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents. Takeshita T, Wu W, Koike A, Fukuda M and Ohta T. Cancer Chemother Pharmacol. 64(5):1039-46, 2009.
- BRCA1-Associated Protein1 interferes with BRCA1/BARD1 RING heterodimer activity. Nishikawa H, Wu W, Koike A, Kojima R, Gomi H, Fukuda M and Ohta T. Cancer Res. 69(1):111-9, 2009.
- The UPS: a promising target for breast cancer treatment (Review). Sato K, Rajendra E, and Ohta T. BMC Biochem. 9(suppl 1):S2, 2008.
- The ubiquitin E3 ligase activity of BRCA1 and its biological functions (Review). Wu W, Koike A, Takeshita T, and Ohta T. Cell Div. 3:1, 2008. PMID: 18179693
- Putative tumor suppressor EDD interacts with and up-regulates APC. Ohshima T, Ohta T, Wu W, Koike A, Iwatani T, Henderson M, Watts C.K.W., and Otsubo T. Genes Cells. 12:1339-45, 2007.
- Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Shimo A, Tanikawa C, Nishidate T, Lin ML, Matsuda K, Park JH, Ueki T, Ohta T, Hirata K, Fukuda M, Nakamura Y, Katagiri T. Cancer Sci. 99:62-70, 2007.
- BRCA1 ubiquitinates RPB8 in response to DNA damage. Wu W, Nishikawa H, Hayami R, Sato K, Honda A, Aratani S, Nakajima T, Fukuda M, Ohta T. Cancer Res. 67:951-8, 2007. プロテオミクスを用いたスクリーニングにてBRCA1/BARD1ユビキチンリガーゼのもう一つの基質としてRNAポリメラーゼの共通サブユニットであるRPB8を同定した論文です。DNA損傷に反応してBRCA1/BARD1はRPB8をユビキチン化します。
- Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Shimo A, Nishidate T, Ohta T, Fukuda M, Nakamura Y, Katagiri T. Cancer Sci. 98:174-81, 2007 .
- Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. Yamasaki S, Yagishita N, Sasaki T, Nakazawa M, Kato Y, Yamadera T, Bae E, Toriyama S, Ikeda R, Zhang L, Fujitani K, Yoo E, Tsuchimochi K, Ohta T, Araya N, Fujita H, Aratani S, Eguchi K, Komiya S, Maruyama I, Higashi N, Sato M, Senoo H, Ochi T, Yokoyama S, Amano T, Kim J, Gay S, Fukamizu A, Nishioka K, Tanaka K, Nakajima T. EMBO J. 26:113-22, 2007.
- A FancD2-Monoubiquitin Fusion Reveals Hidden Functions of Fanconi Anemia Core Complex in DNA Repair. Matsushita N, Kitao H, Ishiai M, Nagashima N, Hirano S, Okawa K, Ohta T, Yu DS, McHugh PJ, Hickson ID, Venkitaraman AR, Kurumizaka H, Takata M. Mol. Cell, 19:841-7, 2005.
- Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. Hayami R, Sato K, Wu W, Nishikawa T, Hiroi J, Ohtani-Kaneko R, Fukuda M, Ohta T. Cancer Res., 65:6-10, 2005.
- Essential role of synoviolin in embryogenesis. Yagishita N, Ohneda K, Amano T, Yamasaki S, Sugiura A, Tsuchimochi K, Shin H, Kawahara K, Ohneda O, Ohta T, Tanaka S, Yamamoto M, Maruyama I, Nishioka K, Fukamizu A, Nakajima T. J. Biol. Chem., 280(9):7909-16, 2005.
- Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. Hu J, McCall CM, Ohta T, Xiong Y. Nat. Cell Biol., 6:1003-9, 2004.
- Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. Sato K, Hayami R, Wu W, Nishikawa T, Nishikawa H, Okuda Y, Ogata H, Fukuda M, Ohta T. J. Biol. Chem., 279:30919-22, 2004.
BRCA1とBARD1によって触媒されるユビキチン化がそれまでに最もポピュラーと考えられていた蛋白質分解を誘導するユビキチン鎖とは異なることを報告した。
- Ubiquitin and Breast Cancer. (Review) Ohta T, and Fukuda M. Oncogene, 23:2079-88, 2004.
- Mass Spectrometric and Mutational Analyses Reveal Lys-6-linked Polyubiquitin Chains Catalyzed by BRCA1-BARD1 Ubiquitin Ligase. Nishikawa H, Ohoka S, Sato K, Arima K, Okamoto J, Klevit R, Fukuda M, and Ohta T. J. Biol. Chem., 279:3916-24, 2004.
- A truncated splice variant of BARD1 that lacks the RING finger and ankyrin repeats. Tsuzuki M, Wu W, Nishikawa H, Hayami R, Oyake D, Yabuki Y, Fukuda M, Ohta T. Cancer Lett. 233:108-16, 2006.
- Binding and recognition in the assembly of an active BRCA1-BARD1 ubiquitin ligase complex. Brzovic PS, Keeffe JR, Nishikawa H, Miyamoto K, Fox D, Fukuda M, Ohta T, and Klevit R. Proc. Natl. Acad. Sci. U. S. A. 100: 5646-5651, 2003.
- Sensitization of head and neck squamous cell carcinoma cells to Fas-mediated apoptosis by the inhibition of Bcl-X(L) expression. Otani Y, Tsutsumi K, Kuwahara D, Oyake D, Ohta T, Nishikawa H, Koizuka I. Auris Nasus Larynx. 30 Suppl:S79-84, 2003.
- Inhibition of caspase-9 activity and Apaf-1 expression in cisplatin-resistant head and neck squamous cell carcinoma cells. Kuwahara D, Tsutsumi K, Oyake D, Ohta T, Nishikawa H, Koizuka I. Auris Nasus Larynx. 30 Suppl:S85-8, 2003.
- Activation of UBC5 Ubiquitin-conjugating Enzyme by the RING Finger of ROC1 and Assembly of Active Ubiquitin Ligases by All Cullins. Furukawa M, Ohta T, Xiong Y. J. Biol. Chem. 277:15758-65, 2002.
- Targeted substrate degradation by an engineered double RING ubiquitin ligase. Oyake D, Nishikawa H, Koizuka I, Fukuda M, Ohta T. Biochem Biophys Res Commun. 295(2):370-5. 2002
- In vitro ubiquitination of cyclin D1 by ROC1-CUL1 and ROC1-CUL3. Maeda I, Ohta T, Koizumi H, Fukuda M. FEBS Lett. 494(3):181-5. 2001.
- The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. Hashizume, R., Fukuda, M., Maeda, I., Nishikawa, H., Oyake, D., Yabuki, Y., Ogata, H., and Ohta, T. J. Biol. Chem. 276:14537-40, 2001.
家族性乳癌の原因遺伝子で、現在は散発性乳癌（家族性でない通常の乳癌）との関連も注目されているBRCA1が、ユビキチンリガーゼという酵素であることを世界に先駆けて報告した。BRCA1はBARD1とRINGヘテロダイマー型のユビキチンリガーゼを形成し、家族性乳癌の原因となるBRCA1の変異によってその酵素活性は死活した。
- Phosphorylation- and Skp1-independent in vitro ubiquitination of E2F1 by multiple ROC-cullin ligases. Ohta, T., and Xiong, Y. Cancer Res. 61:1347-53, 2001.
- The CUL1 C-terminal sequence and ROC1 are required for efficient nuclear accumulation, NEDD8 modification and ubiquitin ligase activity of CUL1. Furukawa M, Zhang Y, McCarville J, Ohta T, Xiong Y. Mol. Cell. Biol. 20: 8185-97, 2000.
- Stem-Loop Binding Protein, the Protein That Binds the 3' End of Histone mRNA, Is Cell Cycle Regulated by Both Translational and Posttranslational Mechanisms. Whitfield ML, Zheng LX, Baldwin A, Ohta T, Hurt MM, Marzluff WF. Mol. Cell. Biol. 20:4188-98, 2000.
- Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen. Fukuda M, Yamaguchi S, Ohta T, Nakayama Y, Ogata H, Shimizu K, Nishikawa T, Adachi Y, Fukuma E. Oncology. 13(7 Suppl 3):77-81, 2000.
- Association with Cullin Partners Protects ROC Proteins from Proteasome-Dependent Degradation. Ohta T., Michel JJ., Xiong Y. Oncogene 18: 6758-66, 1999.
- ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Ohta T., Michel JJ., Schottelius AJ., Xiong Y. Mol. Cell 3:535-41, 1999.
細胞周期を制御するユビキチンリガーゼSCFをはじめとする全てのCullin複合体のサブユニットとしてROC1を単離し、世界で初めてRINGフィンガーモチーフの変異によってユビキチンリガーゼ活性が死活することを示した。この発見の後、多くのRING型ユビキチンリガーゼが発見され、現在ではCullin複合体をあわせて1000種類以上にのぼると考えられている。BRCA1もそのうちの１つである。
- T-loop deletion of CDC2 from breast cancer tissues eliminates binding to cyclin B1 and cyclin-dependent kinase inhibitor p21. Ohta T, Okamoto K, Isohashi F, Shibata K, Fukuda M, Yamaguchi S, Xiong Y. Cancer Res. 58(6):1095-8, 1998.
- Analysis of Cdc2 and Cyclin D1 Expression in Breast Cancer by Immunoblotting. Ohta T, Fukuda M, Arima K, Kawamoto H, Hashizume R, Arimura T, Yamaguchi S. Breast Cancer. 4:17-24. 1997.
- Behavior of the cell cycle-associated proteins in an unusual G0-arrestable cancer cell line. Ohta T, Fukuda M, Wanebo HJ, Jogo K, Yamaguchi S. Exp Cell Res. 225:85-92. 1996.
- Expression of beta-catenin in normal breast tissue and breast carcinoma: a comparative study with epithelial cadherin and alpha-catenin. Hashizume R, Koizumi H, Ihara A, Ohta T, Uchikoshi T. Histopathology. 29:139-46, 1996.
- Prospective evaluation of skin surface electropotentials in Japanese patients with suspicious breast lesions. Fukuda M, Shimizu K, Okamoto N, Arimura T, Ohta T, Yamaguchi S, Faupel ML. Jpn J Cancer Res. 87(10):1092-6, 1996.
- Alterations in CD45 glycosylation pattern accompanying different cell proliferation states. Ohta T, Kitamura K, Maizel AL, Takeda A. Biochem Biophys Res Commun. 200:1283-9, 1994.
- Molecular cloning of the CD45-associated 30-kDa protein. Takeda A, Maizel AL, Kitamura K, Ohta T, Kimura S. J Biol Chem. 269:2357-60, 1994.
- Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer. Ohta T, Kikuchi H, Ogata H, Iwata K, Yoshida K, Katayama K, Watanabe H. Cancer. 70:741-8. 1992.
解説者（太田智彦）が初めて書いた英語論文です。
和文総説
- 太田智彦. 遺伝性乳癌に対する遺伝子修復不全標的治療 乳癌診療 state of the art - 科学に基づく最新診療 第3章 遺伝性乳癌の治療コンセプト 26-30、2022.
- 郷田敦史、呉文文、太田智彦. BRCA遺伝子変異による臓器特異的な発がん 医学のあゆみ Vol.274 (12) 1194-1198、2020.
- 太田智彦. 乳腺腫瘍学 第2章-7.BRCA変異診断、ゲノム診断 日本乳癌学会 第3版 157-160、2020.
- 朱明章、呉文文、太田智彦. がん治療分子標的としてのDNA相同組み換え修復異常 がん分子標的治療 Vol.17(1)69-76、2019.
- 朱明章、太田智彦. DNA相同組換え修復とユビキチン メディカル・サイエンス・ダイジェスト Vol.45(4)29-32、2019.
- 太田智彦. BRCA1/2の基礎とPARP阻害剤 乳癌の臨床 Vol.33(1)31-39、2018.
- 頼勇強、太田智彦. 臨床医のための乳腺基礎医学「乳癌におけるDNA損傷と修復不全」 メディカルレビュー社 Vol.4(1)20-24、2018.
- 櫻井晃洋、太田智彦、赤木究、和泉美紀子、三木義男. 遺伝性乳癌卵巣癌症候群（HBOC)診療の手引き 2017年版 Ⅱ-1.遺伝子診断・遺伝カウンセリング領域 金原出版 29-72、2017.
- 太田智彦. 乳癌学－最新の診断と治療－ Ⅲ.乳癌の分子生物学と発症機序「DNA修復不全と乳癌」 日本臨牀 Vol.75増刊号 (3) 129-134、2017.
- 扇屋りん、太田智彦. 癌の発症と治療におけるユビキチン系の役割 医学のあゆみ Vol.256 (8) 868-873、2016.
- 佐藤工、太田智彦. 乳癌治療におけるユビキチン修飾 医学のあゆみ Vol.243 (6) 520-524、2012.
- 福田貴代、セドキーナ・アンナ、太田智彦. 「乳癌―基礎と臨床の最新研究動向―」Ⅲ 乳癌の分子生物学と発癌機序 1.分子生物学 （2）癌遺伝子と癌抑制遺伝子 日本臨牀 2012年増刊 66-70、2012.
- セドキーナ・アンナ、福田貴代、太田智彦. BRCA1とDNA損傷応答. 生化学 Vol.84 (7) 529-538、2012.
- 太田智彦、西川裕之. DNA相同組換え修復と乳癌. Medical Science Digest Vol.38 (1) 637-640、2012.
- 太田智彦. DNA損傷応答と乳癌の薬剤感受性. 乳癌の臨床 25: 609-615、2010.
- 太田智彦. 遺伝子診療学―遺伝子診断の進歩とゲノム治療の展望―、（１）遺伝子診断、B各論、がんのゲノム解析と診療への応用「乳がん」. 日本臨牀 984: 438-43、2010.
- 太田智彦. BRCA遺伝子異常と標的治療. がん分子標的治療 4: 46-58、2010.
- 岩谷胤生、太田智彦 乳房・乳腺・胸筋の局所解剖. 手術 62:691-697、2008.
- 小池彩華、太田智彦. 治療効果予測マーカー —最近のトピック、Basal-like 乳癌に焦点をあてて—. 日本臨牀 65, suppl 6: 285-290、2007.
- 太田智彦. 8 乳腺、A形態異常、機能異常、B炎症、C良性腫瘍、E乳腺症. 新臨床外科学—第４版— p819-828、p846-847、2006.
- 太田智彦. 乳癌および卵巣癌抑制遺伝子BRCA1. PNE:蛋白核酸酵素 51:1395-1400、2006.
- 太田智彦、福田護. BRCA1ユビキチンリガーゼと乳癌. 医学のあゆみ 211:49-53、2004.
- 太田智彦、速水亮介、呉文文、福田護. 乳癌抑制遺伝子BRCA1. 現代医療 36:953-959、2004.
- 太田智彦、橋詰倫太郎、福田護. BRCA1遺伝子と予防的両側乳房切除術。乳癌の臨床 17:210-216、2002.
- 太田智彦、橋詰倫太郎、福田護. BRCA1のもう1つの機能、ユビキチンリガーゼ活性. 細胞工学 20: 854-856, 2001.